IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro

Annals of the Rheumatic Diseases

Volumn 76, Issue 7, 2017, Pages 1300-1308

  Boutet, Marie Astrid ^a,b   Najm, Aurélie ^a,b,c   Bart, Géraldine ^a,b,c   Brion, Régis ^a,b   Touchais, Sophie ^c   Trichet, Valérie ^a,b   Layrolle, Pierre ^a,b   Gabay, Cem ^d,e   Palmer, Gaby ^d,e   Blanchard, Frédéric ^a,b   Le Goff, Benoit ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Arthritis; Cytokines; Inflammation

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 38; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CONDITIONED MEDIUM; IL-38 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BONE DESTRUCTION; CARTILAGE DEGENERATION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE SEVERITY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SYNOVIOCYTE; TH17 CELL; ANIMAL; ARTICULAR CARTILAGE; BONE; CELL LINE; CONDITIONED MEDIUM; CYTOLOGY; DIAGNOSTIC IMAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL ARTHRITIS; GENETICS; IMMUNOLOGY; MICRO-COMPUTED TOMOGRAPHY; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIUM; WESTERN BLOTTING;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; BONE AND BONES; CARTILAGE, ARTICULAR; CELL LINE; CULTURE MEDIA, CONDITIONED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; IN VITRO TECHNIQUES; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-6; INTERLEUKINS; MACROPHAGES; MICE; REAL-TIME POLYMERASE CHAIN REACTION; SYNOVIAL MEMBRANE; TH17 CELLS; TRANSCRIPTOME; TUMOR NECROSIS FACTOR-ALPHA; X-RAY MICROTOMOGRAPHY;

EID: 85019823243     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210630     Document Type: Article

References (33)

1. Lin H, Ho AS, Haley-Vicente D, et al. Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J Biol Chem 2001;276:20597-602.
2. Mora J, Schlemmer A, Wittig I, et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol. 2016;8:426-38.
3. Boutet MA, Bart G, Penhoat M, et al. Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease. Clin Exp Immunol 2016;184:159-73.
4. Chou CT, Timms AE, Wei JCC, et al. Replication of association of IL1 gene complex members with ankylosing spondylitis in Taiwanese Chinese. Ann Rheum Dis 2006;65:1106-9.
5. Jung MY, Kang SW, Kim SK, et al. The interleukin-1 family gene polymorphisms in Korean patients with rheumatoid arthritis. Scand J Rheumatol 2010;39:190-6.
6. Guo ZS, Li C, Lin ZM, et al. Association of IL-1 gene complex members with ankylosing spondylitis in Chinese Han population. Int J Immunogenet 2010;37:33-7.
7. Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 2011;123:731-8.
8. Rahman P, Sun S, Peddle L, et al. Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 2006;54:2321-5.
9. Rudloff I, Godsell J, Nold-Petry CA, et al. Brief report: interleukin-38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol Hoboken NJ 2015;67:3219-25.
10. Wang HJ, Jiang YF, Wang XR, et al. Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B. World J Gastroenterol 2016;22:4529-37.
11. Zhong Y, Yu K, Wang X, et al. Elevated plasma IL-38 concentrations in patients with acute ST-segment elevation myocardial infarction and their dynamics after reperfusion treatment. Mediators Inflamm 2015;2015:490120.
12. Chu M, Chu IMT, Yung ECM, et al. Aberrant expression of novel cytokine IL-38 and regulatory T lymphocytes in childhood asthma. Molecules 2016;21:933.
13. Wang M, Wang B, Ma Z, et al. Detection of the novel IL-1 family cytokines by QAH-IL1F-1 assay in rheumatoid arthritis. Cell Mol Biol (Noisy-le-grand) 2016;62:31-4.
14. Takenaka S, Kaieda S, Kawayama T, et al. IL-38: a new factor in rheumatoid arthritis. Biochem Biophys Rep 2015;4:386-91.
15. van de Veerdonk FL, Stoeckman AK, Wu G, et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci USA 2012;109:3001-5.
16. Payne KA, Lee HH, Haleem AM, et al. Single intra-articular injection of adeno-associated virus results in stable and controllable in vivo transgene expression in normal rat knees. Osteoarthritis Cartilage 2011;19:1058-65.
17. Guihard P, Boutet MA, Brounais-Le Royer B, et al. Oncostatin m, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury. Am J Pathol 2015;185:765-75.
18. Le Goff B, Soltner E, Charrier C, et al. A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther 2009;11:R185.
19. Guihard P, Danger Y, Brounais B, et al. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells Dayt Ohio 2012;30:762-72.
20. David E, Tirode F, Baud'huin M, et al. Oncostatin M is a growth factor for Ewing sarcoma. Am J Pathol 2012;181:1782-95.
21. Brounais B, David E, Chipoy C, et al. Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells. Bone 2009;44:830-9.
22. Zeng C, Wang W, Yu X, et al. Pathways related to PMA-differentiated THP1 human monocytic leukemia cells revealed by RNA-Seq. Sci China Life Sci 2015;58:1282-7.
23. Brentano F, Ospelt C, Stanczyk J, et al. Abundant expression of the interleukin (IL) 23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis. Ann Rheum Dis 2009;68:143-50.
24. Gabay C, Marinova-Mutafchieva L, Williams RO, et al. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis. Arthritis Rheum 2001;44:451-62.
25. Schett G, Elewaut D, McInnes IB, et al. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med 2013;19:822-4.
26. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010;129:311-21.
27. Scheibel M, Klein B, Merkle H, et al. IkappaBbeta is an essential co-activator for LPS-induced IL-1beta transcription in vivo. J Exp Med 2010;207:2621-30.
28. Ruscitti P, Cipriani P, Carubbi F, et al. The role of IL-1β in the bone loss during rheumatic diseases. Mediators Inflamm 2015;2015:782382.
29. Hong MH, Williams H, Jin CH, et al. The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine-phosphorylated proteins. J Bone Miner Res 2000;15:911-18.
30. Korganow AS, Ji H, Mangialaio S, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999;10:451-61.
31. Wong PKK, Quinn JMW, Sims NA, et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 2006;54:158-68.
32. Wooley PH, Whalen JD, Chapman DL, et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993;36:1305-14.
33. Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity. J Biol Chem 2011;286:42594-602.